Amphastar Pharmaceuticals, Inc. Non Peo Neo Avg Comp Actually Paid Amt
Amphastar Pharmaceuticals, Inc. (AMPH) reported Non Peo Neo Avg Comp Actually Paid Amt of $1.39 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-13.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-13
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $1.39M DEF 14A · filed 2026-04-13 |
| 2024-12-31 | -$1.73M DEF 14A · filed 2026-04-13 |
| 2023-12-31 | $8.79M DEF 14A · filed 2026-04-13 |
| 2022-12-31 | $3.86M DEF 14A · filed 2026-04-13 |
| 2021-12-31 | $2.89M DEF 14A · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |